Last update 21 Nov 2024

Ketamine Hydrochloride

Last update 21 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryKetamine is a small molecule drug that acts as a modulator at the N-methyl-D-aspartate (NMDA) receptor. It is marketed under the trade name KETALAR and is primarily used as an anesthetic drug. Ketamine was first approved for medical use in the United States in 1970 by Endo International. This drug is available as a slightly acidic, sterile solution for intravenous or intramuscular injection. Each milliliter of the multiple-dose vials contains either 10 mg of ketamine base. Ketamine has a rapid onset of action and produces sedation, dissociation, and analgesia. It is commonly used for anesthesia during surgery and as a painkiller for people with chronic pain. Ketamine may have some potential as an antidepressant, but more research is needed to determine its efficacy and safety for this indication. The use of ketamine as an anesthetic or painkiller may cause some side effects, including hallucinations, nausea, and vomiting.

Drug Type

Small molecule drug

Synonyms

(+-)-Ketamine, (±)-ketamine, 2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone

+ [36]

Target

NMDA receptor

Mechanism

NMDA receptor modulators(Glutamate [NMDA] receptor modulators)

Therapeutic Areas

Other DiseasesNervous System DiseasesCongenital Disorders+ [5]

Active Indication

AnesthesiaPainBipolar and Related Disorders+ [18]

Inactive Indication

Amyotrophic Lateral SclerosisAutism Spectrum DisorderBunion+ [5]

Originator Organization

Endo International Plc

Active Organization

PharmaTher Holdings Ltd.

NeuroRx, Inc.

Psycheceutical, Inc.Startup

+ [17]

Inactive Organization

Novartis Pharma AG

Douglas Pharmaceuticals Ltd.

Roivant Sciences, Inc.

+ [1]

Drug Highest PhaseApproved

First Approval Date

US (19 Feb 1970),

Anesthesia

RegulationFast Track (US), Orphan Drug (US), Innovative Licensing and Access Pathway (GB)

Structure

Molecular FormulaC13H16ClNO

InChIKeyYQEZLKZALYSWHR-UHFFFAOYSA-N

CAS Registry6740-88-1

View All Structures (2)

1,856

Clinical Trials associated with Ketamine Hydrochloride

IRCT20161022030421N3 / SuspendedPhase 3IIT

Comparison of the effect of intravenous ketamine and midazolam as a premedication in children undergoing cochlear implantation at the time of separation from parents

Start Date21 Jan 2640

Sponsor / Collaborator-

NCT04291521 / Not yet recruitingNot ApplicableIIT

Prospective Study of Induction Medications Used in the Rapid Sequence Intubation of Trauma Patients and a Comparison of Effects on Outcomes

To compare the outcomes of the use of propofol, etomidate, and ketamine as induction agents for adult trauma patients undergoing intubation within 24 hours of admission. The primary goal is to determine the ideal agent that should be used in this patient population for intubations.

Start Date01 Jan 2026

Sponsor / Collaborator

University of Southern California

[+4]

NCT06419439 / Not yet recruitingPhase 2IIT

Ketamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression

This is a pilot study to evaluate the feasibility, acceptability, and safety of ketamine infusions followed by a brief behavioral intervention in Veterans with chronic low back pain and depression.

Start Date01 Dec 2025

Sponsor / Collaborator

VA Office of Research and Development

100 Clinical Results associated with Ketamine Hydrochloride

100 Translational Medicine associated with Ketamine Hydrochloride

100 Patents (Medical) associated with Ketamine Hydrochloride

27,426

Literatures (Medical) associated with Ketamine Hydrochloride

01 Feb 2025·Behavioural Brain Research

Involvement of the serotonergic, GABAergic and glutamatergic systems of the rostral anterior cingulate cortex in the trait and state anxiety of adult male Wistar rats.

Article

Author: Franco, Heitor Santos ; Melo, João Eduardo Conceição ; Menezes, Edênia Cunha de ; Santos, José Ronaldo Dos ; Goes, Tiago Costa ; Marchioro, Murilo ; dos Santos, José Ronaldo ; Silva, Rodolfo Santos ; Oliveira e Silva, Ana Mara de ; de Menezes, Edênia Cunha ; Teixeira-Silva, Flavia ; Oliveira E Silva, Ana Mara de ; Almeida-Souza, Thiago Henrique ; Santos, Leandra Martins

Despite significant advancements to understand of the neural circuitry involved in anxiety, the neurobiology of trait anxiety remains unclear. The rostral anterior cingulate cortex (rACC) and various pathways have been implicated in its regulation, making it a key to trait anxiety. The present study aimed to investigate the role of these neurotransmitter systems in the rACC in trait anxiety. Since trait anxiety is known to modulate state anxiety, we further investigated this relationship. Specifically, in Experiment I, we used animals with high trait anxiety; in Experiment II, we used animals with low trait anxiety; and in Experiment III, we used animals with medium trait anxiety. Before each behavioral assessment, drugs that either increased or decreased serotonergic (Fluoxetine or WAY-100635), GABAergic (Muscimol or Bicuculline), and glutamatergic (NMDA or Ketamine) neurotransmission in the rACC were administered, along with their respective controls. Additionally, in Experiment IV, all animals from the previous experiments were subjected to the Elevated Plus Maze (EPM) and Hole board (HB) test and evaluated without taking into account their trait anxiety levels. The results of the present study showed that, in Exp I, the modulation of the serotonergic, GABAergic and glutamatergic systems in the rACC decreased trait anxiety in highly anxious rats, while by submitting the animals to HB, the administration of fluoxetine increased state anxiety. In Exp II, the modulation of all systems increased trait anxiety in rats with low trait anxiety, whereas, in HB, state anxiety levels were increased with the administration of NMDA. In Exp III, only the modulation of the glutamatergic system, with NMDA, increased both trait and state anxiety levels. However, none of the evaluated neurotransmitter systems altered the state anxiety modeled in the EPM. Overall, the results of the present study provide new insights into the role of the neurotransmitter systems in the rACC in the regulation of trait anxiety and state anxiety.

01 Feb 2025·Journal of Affective Disorders

Effect of ketamine on task-based functional magnetic resonance imaging findings in major depressive disorder: A mini-review

Review

Author: Schiena, Giandomenico ; Sambataro, Fabio ; Cattarinussi, Giulia ; Delvecchio, Giuseppe ; Nemati, Fatemeh ; Mardani, Peyman ; Ramezani, Farzaneh ; Brambilla, Paolo

BACKGROUNDOver the last two decades, ketamine has gained significant interest in psychiatry as a potential treatment for major depressive disorder (MDD), especially in individuals who are resistant to traditional therapies or are at a high risk of suicide. Task-based functional magnetic resonance imaging (fMRI) studies can provide insight into how ketamine alters brain function and contributes to its antidepressant properties.METHODSThis mini-review followed the MOOSE guidelines for systematic reviews of observational studies. We conducted a literature search in PubMed, Web of Science, and Scopus aiming at identifying fMRI studies investigating the effect of ketamine on brain function in MDD.RESULTSEight articles were included in the study. Results showed that ketamine affects brain activity in MDD, especially in the anterior cingulate cortex (ACC), dorsolateral prefrontal cortex, and amygdala. Interestingly, the majority of the reviewed studies showed a correlation between the changes in brain activity induced by ketamine and improvements in clinical depressive symptoms. These correlations involved the prefrontal cortex, ACC, and cortico-cerebellar circuits.LIMITATIONSLack of longitudinal data on the lasting effects of ketamine on brain activity and the small number of studies.CONCLUSIONSThis review identifies key research areas that can enhance our understanding of ketamine's effects on the brain in MDD. It calls for studies on ketamine's mechanisms of action, long-term impact, dose-response optimization, and comparisons with other fast-acting antidepressants. Addressing these areas can optimize ketamine's therapeutic use and reveal new treatment targets.

01 Feb 2025·Current Neuropharmacology

Comparison of the Antianhedonic Effects of Repeated-dose Intravenous Ketamine in Older and Younger Adults with Major Depressive Episode

Article

Author: Zheng, Wei ; Zhang, Bin ; Lan, Xiaofeng ; Li, Zezhi ; Tan, Jianqiang ; Gu, Limei ; Zhou, Yanling ; Ning, Yuping ; Wang, Chengyu

Objectives:Growing evidence suggests that repeated-dose intravenous ketamine in patients with depression had rapid antianhedonic effects. However, a comparison of the antianhedonic effects of repeated-dose intravenous ketamine between younger adults and older depressed patients has not been examined.Methods:To the best of my knowledge, this study with a total of 135 patients with major depressive episodes (MDE) is the first to compare the antianhedonic effects between younger adult (n = 116) and older (n = 19) depressed patients receiving six ketamine infusions (0.5 mg/kg over 40 min). Montgomery- Åsberg Depression Rating Scale (MADRS) was applied in this study to evaluate the clinical symptoms, and MADRS anhedonia item scoring was used to evaluate anhedonia symptoms.Results:Patients received six open-label intravenous infusions of ketamine for 12 days. MADRS anhedonia subscale scores decreased in both younger (3.3, 95% CI = 2.5-4.1, p < 0.05) and older (2.8, 95% CI = 1.1-4.6, p < 0.05) MDE patients at 4h after the first infusion compared to baseline scores and the reduction was maintained over the subsequent infusion period in both groups (all Ps < 0.05). Younger MDE patients had lower MADRS anhedonia subscale scores on day 26 compared with older patients (P = 0.02). Compared with younger adult MDE patients, older patients had a lower antianhedonic response (51.7% [95% CI = 42.5%-61.0%] versus 31.6% [95% CI = 8.6%-54.6%)] and remission (24.1% [95% CI = 16.2%-32.0%] versus 0%).Conclusion:This study indicates that repeated-dose intravenous ketamine administration induces rapid and robust antianhedonic effects in older MDE patients. However, older MDE patients displayed less response to ketamine than younger adult MDE patients.

574

News (Medical) associated with Ketamine Hydrochloride

18 Nov 2024

·www.prnewswire.com

NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial Officer

Industry veteran with extensive experience in key areas of focus Interim-CFO Richard Narido to focus on HOPE Therapeutics acquisition opportunities WILMINGTON, Del., Nov. 18, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced it has appointed Michael Abrams as its permanent Chief Financial Officer. Mr. Abrams succeeds Interim-CFO Richard Narido, who will continue to support the Company's financial function and other projects. Continue Reading HOPE Therapeutics, Inc. (PRNewsfoto/NRx Pharmaceuticals, Inc.) "We are delighted to welcome Mike to the NRx team. Mike's combination of public company CFO experience in the biotechnology sector, together with investment banking expertise is ideally suited to NRx's needs as we aim to become a revenue generating, profitable biotechnology company," said Dr. Jonathan Javitt, Chairman, CEO and Chief Scientist of NRx Pharmaceuticals. "Additionally, we thank Rich for his outstanding service to the Company as our Interim-CFO and look forward to his ongoing contributions as HOPE Therapeutics continues to grow its business." Mr. Abrams commented "I'm delighted to join NRx at this critical juncture in the Company's evolution. Evolving from a pre-revenue biotechnology company into a profitable enterprise is both a tremendous opportunity and challenge. I look forward to helping grow the Company with the NRx team." Michael Abrams is a senior finance professional with almost three decades of experience as an executive officer, investment banker, director and senior advisor, which includes serving as the Chief Financial Officer of Arch Therapeutics, RiseIT Solutions. and FitLife Brands. Mr. Abrams has deep experience across multiple functional areas including, but not limited to, financial operations, accounting, mergers and acquisitions, financial engineering, capital raising and shareholder communications. He earned his MBA with Honors from the University of Chicago Booth School of Business following his BBA with Honors from the University of Massachusetts at Amherst, where he was named a William F. Field alumni scholar. About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI. NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality. About HOPE Therapeutics, Inc. HOPE Therapeutics, Inc. () is a development stage healthcare delivery company developing a best-in-class network of precision psychiatry clinics that intends to offer ketamine transcranial magnetics stimulation (TMS) and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy. Notice Regarding Forward-Looking Statements The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, liquidity, Hope Therapeutic's ability to consummate the acquisitions of providers for its national network, the Company's ability to raise adequate capital to fund the Hope Therapeutics acquisitions, and the Company's ability to spin-off Hope Therapeutics. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at . Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise. For further information: Matthew Duffy Chief Business Officer, NRx Pharmaceuticals Co-Chief Executive Officer, HOPE Therapeutics, Inc. [email protected] SOURCE NRx Pharmaceuticals, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Executive ChangeFast Track

18 Nov 2024

·www.globenewswire.com

Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders

Dual-action approach combining 5-HT4R Agonist (SPC-15) and NMDAR antagonist demonstrates enhanced efficacy in preclinical study for managing severe conditions The Company is currently developing SPC-15 as an intranasal treatment for PTSD SARASOTA, FL, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced promising results from a preclinical study on SPC-15. This new formulation, which targets both the serotonin 5-HT4 receptor (5-HT4R) and the NMDA receptor (NMDAR), has shown potential as a treatment for major depressive disorder (MDD), and other severe stress-related conditions. The study highlights the proposed efficacy of combining SPC-15, a 5-HT4R agonist, with an NMDAR antagonist to treat stress-induced behaviors. Results from animal models indicate that this dual-target approach may offer additional efficacy in treating severe conditions compared to using either agent alone, suggesting a potential enhanced therapeutic effect for managing severe psychiatric conditions. Key Study Findings Dual Receptor Targeting Yields Superior Results: By simultaneously targeting 5-HT4R and NMDAR, the combined treatment demonstrated significant improvement in behavioral outcomes related to severe stress-induced conditions as compared to using either agent alone.Additive Therapeutic Effects: The combination therapy showed a marked reduction in stress behaviors in animal models, indicating potential benefits for patients suffering from treatment-resistant depression. “We are encouraged by these results, which point to what we believe is a promising new approach for managing severe stress-related psychiatric disorders,” said Eric Weisblum, CEO of Silo Pharma. “In our opinion, our dual-action strategy with SPC-15 demonstrates the potential to provide an effective treatment option for patients experiencing severe and relapsed stress-related disorders. “We believe these findings further support our continuing development of SPC-15 as an intranasal prophylactic treatment for PTSD,” Weisblum added. “We are advancing this program with a goal of an IND submission for first-in-human trials.” About SPC-15SPC-15 is a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for the treatment of PTSD, anxiety, and other stress-induced affective disorders. SPC-15 is being developed as an intranasal medication. If clinically successful, SPC-15 could qualify for the FDA’s streamlined 505(b)(2) regulatory pathway for drug approval. Silo Pharma is conducting preclinical studies of SPC-15 in collaboration with Columbia University and was granted an exclusive license to further develop, manufacture, and commercialize SPC-15 worldwide. About Silo PharmaSilo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. Silo focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The Company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. SP-26 is a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. Silo’s two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). Silo’s research and development programs are conducted through collaborations with universities and independent laboratories. For more information, visit www.silopharma.com and follow Silo Pharma on LinkedIn, X, and Facebook. Forward-Looking StatementsThis news release contains "forward-looking statements" within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events, or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law. Contact Information800-705-0120investors@silopharma.com

License out/inClinical Result

15 Nov 2024

·www.prnewswire.com

Mindbloom and Happier Break New Ground with the Ultimate Fusion of Ketamine Therapy and Mindfulness

AUSTIN, Texas, Nov. 15, 2024 /PRNewswire/ -- Today, Mindbloom, the largest provider of psychedelic therapy, and Happier, the leading meditation and habit-building app, announce Continuous Transformation – a partnership to enable people to deepen their mindfulness practices and unlock emotional healing. Continue Reading Mindbloom and Happier Break New Ground with the Ultimate Fusion of Ketamine Therapy and Mindfulness "As a dedicated meditator for over a decade, I've experienced the profound synergy between ketamine and meditation." said Dylan Beynon, Mindbloom's Founder and CEO. "Ketamine's unique dissociative effects produce a state of undistracted awareness that cuts through mental noise, allowing for clarity and ego dissolution. This isn't just about a breakthrough moment — it's about sustaining transformation." The benefits of ketamine and mindfulness are well-established: 62% of Mindbloom clients report significant improvements in depression or anxiety after four sessions, while Mindfulness-Based Stress Reduction reduces anxiety in 70-80% of individuals. When combined, their effects are even more powerful: Ketamine quiets the mind and disrupts thought loops, providing a foundation for mindfulness, while meditation trains the mind to observe thoughts without attachment. Ketamine enhances neuroplasticity, enabling the brain to form new neural connections and break free from entrenched thought patterns, creating fertile ground for growth. Meditation sustains ketamine's effects, helping people process emotional breakthroughs and integrate key insights. "This partnership is a fusion of two powerful modalities that work in harmony to support lasting transformation. Happier's personalized mindfulness journey complements Mindbloom's transformative therapy by providing users with the tools to not only process their breakthroughs but also sustain and integrate them into daily life. Together, we're creating a holistic experience where insight and practice go hand in hand, empowering individuals to experience deep healing and ongoing personal growth" said Sarah Bidnick, Happier's CMO. This launch marks the beginning of a deep partnership: Mindbloom clients receive free access to Happier's mindfulness resources, including 500+ guided meditations from 60+ world-class teachers. Happier users gain discounted access to Mindbloom's programs, including 12 pathways for challenges like anxiety, depression, PTSD, and self-love, complete with integration content and personalized coaching. Phase two, launching next year, will introduce "Meditation for Mindbloom, Powered by Happier" — a collection of Happier meditations seamlessly integrated into the Mindbloom app. About Mindbloom: Mindbloom is the largest provider of psychedelic medicine, offering ketamine therapy programs that combine medicine with coaching, content, and community. Mindbloom's clinicians facilitate over 275,000 at-home ketamine therapy sessions each year in 36 states, and Mindbloom's treatment outcomes were published in the largest study of ketamine therapy. About Happier: Happier is a meditation app that meets you where you are, so you can realize more than you ever thought possible. With a flexible approach and wisdom from some of the world's most insightful teachers, Happier helps you get more out of meditation — so you can give more to every part of your life. Happier creates a personalized meditation plan for you based on your monthly check in answers. Every day, you'll receive fresh, tailored meditations and activities from our extensive library to guide your practice. Contact: Anna Gotskind 773-633-6606 [email protected] SOURCE Mindbloom WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2

100 Deals associated with Ketamine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D00711	Ketamine Hydrochloride	N01AX03	DBSALT000396

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anesthesia	US	Endo Operations Ltd.	19 Feb 1970
Pain	CA	-	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bipolar and Related Disorders	Phase 3	US	NeuroRx, Inc.	30 Jan 2022
Depressive Disorder	Phase 3	US	NeuroRx, Inc.	25 Jun 2019
Suicidal Ideation	Phase 3	US	NeuroRx, Inc.	25 Jun 2019
Alcohol Use Disorder	Phase 3	GB	Awakn Life Sciences Corp.	-
Acute Pain	Phase 2	-	iX Biopharma Ltd.	-
Alcoholism	Phase 2	-	Awakn Life Sciences, Inc.	-
Parkinsonian Disorders	Phase 2	US	PharmaTher Holdings Ltd.	-
Depressive Disorder, Treatment-Resistant	Phase 1	US	Novartis Pharma AG	08 Feb 2019
Depressive Disorder, Treatment-Resistant	Phase 1	ES	Novartis Pharma AG	08 Feb 2019
Bunion	Phase 1	US	iX Biopharma Ltd.	24 Aug 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04889664 (CTgov)	Phase 2	Stress Disorders, Post-Traumatic	16	Written Exposure Therapy+ketamine	azikqneirg(wpjsukgimj) = zlzfojmmic xbqkmlraii (hxbpqlpplg, lwegpeqkby - wunskvoijk) View more	-	08 Oct 2024
NCT04916548 (CTgov)	Phase 1/2	Depressive Disorder	15	Intravenous Ketamine	puikrngmhn(hempqgewms) = wseswwqtrd zqshabfrnu (ngqktscwca, pjactgdkfy - enidpuiyks) View more	-	20 Aug 2024
NCT05168735 (CTgov)	Phase 1/2	Depressive Disorder	43	Brief Mindfulness Exercises+Intravenous Ketamine (Intravenous Ketamine + Mindfulness Exercises)	(rbslbscvlq) = hpjjuaazpf vimpgtnskc (rsnuobvmmp, iaukqpyxgq - oodshiygym) View more	-	20 Aug 2024
NCT05168735 (CTgov)	Phase 1/2	Depressive Disorder	43	Academic Exercises+Intravenous Ketamine (Intravenous Ketamine + Academic Exercises)	(rbslbscvlq) = qdzrbinokd vimpgtnskc (rsnuobvmmp, mryregxzrr - kkhfnizpel) View more	-	20 Aug 2024
NCT05957302 (Pubmed \| J Anesth) Manual	Not Applicable	Shock, Septic	86	Ketamine 1 mg/kg	dezsrlfjwf(hsotyoqshw) = crrufxloed sjviwenapv (tvqzgjevvf )	Positive	18 Aug 2024
NCT05957302 (Pubmed \| J Anesth) Manual	Not Applicable	Shock, Septic	86	fentanyl 1 mg/kg	dezsrlfjwf(hsotyoqshw) = kumzpdtwof sjviwenapv (tvqzgjevvf )	Positive	18 Aug 2024
NCT04947085 (CTgov)	Phase 4	Pain	150	Ketamine via Intravenous (IV SDK)	hrsvykirgw(yojkfxkbfb) = vrwtjmypfy tyzljzvsrs (iknevbhiwf, bozvvxixit - pcfiuvodjt) View more	-	03 Jul 2024
NCT04947085 (CTgov)	Phase 4	Pain	150	Ketamine via BAN (K-BAN)	hrsvykirgw(yojkfxkbfb) = sxamuoqecv tyzljzvsrs (iknevbhiwf, fgcnrmyism - ojzpxzmjes) View more	-	03 Jul 2024
NCT06236113 (CTgov)	Phase 4	Rib Fractures	50	Ketamine 1 Mg/mL-NaCl 0.9% Intravenous Solution (Placebo/Control)	ojnzsxhkmm(xeyyhitpfm) = tialapcfzo sftlxrllbw (iwhmjldzft, vnkavtgzel - yatoehncdd) View more	-	21 May 2024
NCT06236113 (CTgov)	Phase 4	Rib Fractures	50	Ketamine 1 Mg/mL-NaCl 0.9% Intravenous Solution (Low Dose Ketamine Infusion (LDKI))	ojnzsxhkmm(xeyyhitpfm) = ytkajiobzl sftlxrllbw (iwhmjldzft, xhlfubpbwt - lywttsgpba) View more	-	21 May 2024
ATS2024	Not Applicable	-	-	Ketamine	wdjacwnpjn(xwesesdceb) = Acute Kidney Injury on CKD (Creatinine 4.3 mg/dL) gksrldfnmb (mlqaxbbujt ) View more	-	19 May 2024
ATS2024	Not Applicable	Status Asthmaticus	-	Ketamine infusion	imixnutgqt(gtxplkxryh) = careful monitoring for neuropsychiatric effects zklpbxxrmy (dgmissbysn ) View more	-	19 May 2024
NCT03362073 (CIVIK, Pubmed) Manual	Phase 2	Cancer Pain Adjuvant	20	Ketamine	(ynznsskbgz) = ghbtkpxtfc wbzzsfvvfv (dsmvjeexbg ) View more	Positive	16 May 2024
NCT05193318 (KReDO, CTgov)	Phase 2	Opium Dependence \| Depressive Disorder, Major	5	Ketamine-assisted psychotherapy	doxzzpnqzb(rkatnxjfed) = pxmimjayzi jljiuymabg (mrzaxucxda, gadcurgrfw - lkesxddpwu) View more	-	06 May 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis